| Formerly |
|
|---|---|
| Company type | Public |
| |
| Founded | 1999 |
| Headquarters | , United States |
Key people | Michael Egholm (president & CEO) |
| Revenue |  US$130.6 million (2021)[1] |
Number of employees | 615 (December 2021)[2] |
| Website | standardbio |
Standard BioTools Inc., previously known as Fluidigm Corp., offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs),[3] and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.
Standard BioTools sells products to academic research institutions; translational research and medical centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology and plant and animal research companies; and contract research organizations.
- ^ Linthwaite & Jog 2022, p. 75.
- ^ Linthwaite & Jog 2022, p. 15.
- ^ Dutton, Gail (2015-01-14). "Fluidigm Pioneers Single-Cell Biology". GEN - Genetic Engineering and Biotechnology News. Retrieved 2023-12-11.